- Correlia Biosystems, a Berkeley, CA-based life science startup, closed a $7m Series A financing round
- The round led by Neotribe Ventures, joined by Cota Capital, the Regents of the University of California, and others
- NeoTribe Ventures joins Correlia’s board of directors as part of the financing
- The company also intends to use the funds for the commercial launch of its immunoassay platform
- This will also the first instrument planned in their larger suite of proteomics tools focused on highly efficient and automated protein measurements
- Correlia is launching a product to miniaturize Elisa, a quantitative test for proteins and antibodies widely used in drug development, vaccine development, and diagnostics
